In the multi-organ screen, Elovl1 resulted enriched particularly in the liver of mice treated with anti-PD-1 (Extended Data Fig. 1i) and ranked well in both the primary tumour and lungs of mice treated with anti-PD-1 (position 193 and 153, respectively; Supplementary Table 1), thus highlighting the efficiency of our approach in identifying putative targets having a systemic relevance and synergizing with anti-PD-1 treatment. Here, ELOVL1 is linked to neoplasm.